New Orleans Based Biotech Company MDR Logix’s MDR504 Shows Promise in Neutralizing COVID-19 Virus
New Orleans Based Biotech Company MDR Logix’s MDR504 Shows Promise in Neutralizing COVID-19 Virus
NEW ORLEANS, LA. (July 29, 2020) — MDR Logix, LLC, is pleased to announce that additional testing of its lead product, MDR504, has shown positive results in the continuing fight against COVID-19. According to findings published on bioRxiv (“Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2”), MDR504 has proven to be very effective in an animal model of COVID-19 showing high efficiency (90%+) virus neutralization.
MDR504 is a mutated fusion protein with mutations in the catalytic domain of the ACE2, which abrogates unwanted blood pressure side effects and enhances neutralization of SARS-CoV2 virus. The synthetic protein is fused to human IgG1 that allows stability in serum as well as excellent bioavailability to lung – the site of viral infection.
The study also concluded that the MDR504 therapeutic could serve as a complement to vaccine technology; specifically, for “subjects that may not be good candidates for vaccines such as patients with hematologic or other malignancies, or those that are undergoing immunosuppressive therapy for organ transplantation or autoimmune disease.”
“This significant research shows that MDR504 is the ideal candidate for preventing and treating COVID-19,” says Dr. Ray Chaudhuri, CEO of MDR Logix. “In addition to treating COVID-19, it is our hope that MDR504 can be used for pre or post-exposure therapy for healthcare workers, first responders, vulnerable populations at high risk and to prevent infection in patients with underlying illness who can’t receive a vaccine.”
MDR504 was developed as a therapeutic strategy to outcompete and block SARS-CoV2 virus entry by Dr. Jay Kolls, John W. Deming Endowed Chair in Internal Medicine at Tulane. For more information about MDR Logix, visit www.mdrlogixllc.com.
###
About MDR Logix :
MDR Logix, LLC is a biotech company based out of New Orleans. Due to the high affinity of the SARS-CoV2 spike protein to the human ACE2 (hACE2) receptor, MDR Logix developed a therapeutic strategy to outcompete and block SARS-CoV2 virus entry. The company’s main product, MDR504 is a mutated fusion protein, with mutations in the catalytic domain of the ACE2, which abrogates unwanted blood pressure side effects and enhances neutralization of SARS-CoV2 virus. MDR504 has shown compelling virus neutralization in the nanomolar range compared to the wild type hACE2-Fc. MDR504 is fused to human IgG1 that allows stability in serum as well as excellent bioavailability to lung- the site of viral infection. For more information on MDR Logix, visit www.mdrlogixllc.com.